Global TCR Engineered T-Cell Therapy Technologies, Pipelines, Stakeholders & Deals Report 2018GlobeNewswire (press release)Both receptors deploy T-cells to target the tumor, but CAR T-cells (CAR-T) are limited to binding to cell surface antigens, w… Continue reading
STAT30 years is too long to wait for new medicines. There are ways to speed up drug developmentSTATIn the early 1990s, I co-founded GeneMedicine Inc., one of the first gene therapy companies. It had a successful startup, raised hundreds of millions of … Continue reading
STAT30 years is too long to wait for new medicines. There are ways to speed up drug developmentSTATIn the early 1990s, I co-founded GeneMedicine Inc., one of the first gene therapy companies. It had a successful startup, raised hundreds of millions of … Continue reading
Medical News Today |
Breast cancer: New immunotherapy leads to complete regression
Medical News Today Adoptive cell transfer (ACT), in particular, is a type of immunotherapy that strengthens a specific kind of immune cell: T cells. In ACT, healthcare professionals collect T cells from the malignant tumor and isolate immune cells that are the most … Woman’s late-stage breast cancer falls to immunotherapyScience Magazine What Is Immunotherapy?: Woman With Terminal Breast Cancer Saved by Pioneering TreatmentNewsweek Immunotherapy defeats a breast cancer that had defied other treatmentsChron.com National Institutes of Health (press release) –Fox5NY –Nature all 155 news articles » |
OneNewsNow |
Adult stem cells save life of preborn baby
OneNewsNow “So what they did is gave her blood transfusions to get the swelling down,” says Mattes, “and then with the last blood transfusion, they did an adult stem cell transfusion using the mother’s adult stem cells.” The adult stem cells are taken from the … |
STAT |
Months after a monstrous blowup, a closely watched biotech sets its sights on gene therapy
STAT The pivot to gene therapy is a chance for Ramaswamy, Axovant’s chairman, to write a second act for his neuroscience company. Cheruvu said the Oxford BioMedica deal represents “a strategic shift” for the company, an effort “to push Axovant in the … Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease from Oxford BioMedica and Announces Key …GlobeNewswire (press release) Axovant pivots with new gene therapy, Spark co-founder as CTOFierceBiotech |